Categories: Healthcare

Brain Tumor Drugs Market Growth Trajectory Through 2024-2033|F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc.

The Brain Tumor Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Brain Tumor Drugs Market:
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

According to The Business Research Company’s Brain Tumor Drugs, The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, increased healthcare expenditure, increased number of approvals for oncology (cancer) drugs, increase in pharmaceutical r&d expenditure, and advances in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs, and revised fda regulations to facilitate biologics drug development. Major trends in the forecast period include investing in combination of drugs for brain tumor treatment, adapting the use of phase zero clinical trials to improve efficacy, use of technology for drug delivery that improves the efficacy of the drug, focus on the expansion of cell and gene therapy, and carrying out strategic mergers and acquisitions.

The major driving factor responsible for the growth of the Brain Tumor drugs market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor is leading to a rise in the demand for growth of the brain tumor drugs market drugs used in their treatment.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp

The brain tumor drugs market covered in this report is segmented –

1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users

Companies in the brain tumor drugs market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.

The brain tumor drugs market report table of contents includes: